How often is too often when using lurbinectedin?

How often is too often when using lurbinectedin?

Lurbinectedin is given once every three weeks. The approved dose is 3.2 mg per square meter of body surface area as a one-hour infusion. This schedule comes directly from the FDA-approved prescribing information and the clinical trials that supported its approval for relapsed small cell lung cancer.

How does this schedule affect patients who need repeated doses?

Patients receive infusions on day 1 of each 21-day cycle. The three-week gap gives bone marrow and liver function time to recover. Many patients stay on treatment until disease progression or unacceptable toxicity develops, rather than for a fixed number of cycles.

What happens if a patient tries to shorten the interval between doses?

Reducing the interval raises the risk of severe neutropenia, thrombocytopenia, and liver enzyme elevations. Dose reductions or delays are common when blood counts fall below certain thresholds. The prescribing information recommends checking complete blood counts before each dose.

What side effects are patients asking about with frequent dosing?

Severe neutropenia occurs in roughly 40-50% of patients, severe thrombocytopenia in 20-30%, and severe fatigue in 10-20%. Fatigue, nausea, and loss of appetite are the most common complaints that lead to dose adjustments. Patients who keep low counts or persistent fatigue keep seeing their doses reduced or delayed.

When does lurbinectedin patent expire?

Lurbinectedin itself is not yet patented in the United States. The compound has patents covering composition of matter and use in cancer that extend through 2035 in some jurisdictions. The manufacturer, PharmaMar, has also applied for data exclusivity and new chemical entity protection that push protection further.